Volume 3.36 | Sep 21

Prostate Cell News 3.36 September 21, 2012
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
MicroRNA-106b-25 Cluster Expression Is Associated with Early Disease Recurrence and Targets Caspase-7 and Focal Adhesion in Human Prostate Cancer
Researchers report that microRNAs (miRNAs) encoded by miR-106b-25 are upregulated in both primary tumors and distant metastasis. To identify unknown oncogenic functions of miR-106b, they overexpressed it in LNCaP human prostate cancer cells to examine miR-106b-induced global expression changes among protein-coding genes. [Oncogene] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)


Nuclear Kaiso Indicates Aggressive Prostate Cancers and Promotes Migration and Invasiveness of Prostate Cancer Cells
Researchers found an enrichment of nuclear Kaiso expression in cells of primary and metastatic prostate tumors relative to the normal prostate epithelium. In both DU-145 and PC-3 prostate cancer cell lines, Kaiso inhibition decreased cell migration and invasion, even in the presence of epidermal growth factor. [Am J Pathol] Abstract

Secreted Hsp90 Is a Novel Regulator of the Epithelial to Mesenchymal Transition (EMT) in Prostate Cancer
Scientists identified a novel and pivotal role for extracellular Hsp90 (eHsp90) in driving EMT events in prostate cancer. They demonstrated that eHsp90 promoted cell motility in an ERK and matrix metalloproteinases (MMP)- 2/9-dependent manner, and shifted cellular morphology towards a mesenchymal phenotype. [J Biol Chem] Full Article

Enhancing the Effectiveness of Androgen Deprivation in Prostate Cancer by Inducing Filamin A Nuclear Localization
The authors showed that Filamin A nuclear localization induced apoptosis in castration-resistant prostate cancer cells during androgen deprivation therapy, identifying it as a treatment tool in advanced prostate cancer. [Endocr Relat Cancer] Abstract

In-Depth Investigation of Archival and Prospectively Collected Samples Reveals No Evidence for XMRV Infection in Prostate Cancer
Recent evidence indicates that xenotropic murine leukemia virus-related virus (XMRV) is a contaminant originating from the recombination of two mouse endogenous retroviruses during passaging of a prostate tumor xenograft in mice, generating laboratory-derived cell lines that are XMRV-infected. To confirm or refute an association between XMRV and prostate cancer, investigators analyzed prostate cancer tissues and plasma from a prospectively collected cohort of 39 patients as well as archival RNA and prostate tissue. [PLoS One] Full Article | Press Release

7-Epi-Nemorosone from Clusia rosea Induces Apoptosis, Androgen Receptor Down-Regulation and Dysregulation of Prostate Specific Antigen Levels in LNCaP Prostate Carcinoma Cells
Scientists aimed to characterize the antitumoral activity of the plant compound 7-epi-nemorosone in prostate carcinoma cell lines. They demonstrated that 7-epi-nemorosone exerts cytotoxicity in an androgen-dependent prostate carcinoma entity by targeting the MEK1/2 signal transducer. [Phytomedicine] Abstract

Simultaneous Modulation of the Intrinsic and Extrinsic Pathways by Simvastatin in Mediating Prostate Cancer Cell Apoptosis
The molecular mechanisms by which simvastatin induced apoptosis in prostate cancer cells is not completely understood. Researchers studied the effect of simvastatin on PC3 cell apoptosis compared with docetaxel using apoptosis, TUNEL and trypan blue viability assays. [BMC Cancer] Abstract | Full Article

TGFβ1 Induces Apoptosis in Invasive Prostate Cancer and Bladder Cancer Cells via Akt-Independent, p38 MAPK and JNK/SAPK-Mediated Activation of Caspases
The authors investigated the effect of transforming growth factor-β1 (TGFβ) on the survival and proliferation of invasive prostate (PC3) and bladder (T24) cancer cells. Their study indicated that TGFβ1 decreased cell viability and induced apoptosis in invasive human PC3 and T24 cells via activation of p38 mitogen activated protein kinase (p38 MAPK)-c-jun N-terminal kinase (JNK)-Caspase9/8/3 pathway. [Biochem Biophy Res Commun] Abstract

Ethanol Promotes Cytotoxic Effects of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand through Induction of Reactive Oxygen Species in Prostate Cancer Cells
Scientists demonstrated that ethanol enhances the apoptosis-inducing potential of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in androgen-resistant PC3 cells and sensitizes TRAIL-resistant, androgen sensitive LNCaP cells to apoptosis through caspase activation, and a complete cleavage of poly-ribose polymerase, which was in association with increased production of reactive oxygen species. [Prostate Cancer Prostatic Dis] Abstract

Differential Molecular Mechanism of Docetaxel-Octreotide Combined Treatment According to the Docetaxel-Resistance Status in PC3 Prostate Cancer Cells
Investigators examined the effect and the molecular mechanisms of the combined treatment of the somatostatin analogue octreotide with docetaxel through analysis of proliferation, apoptosis and migration in the human prostate cancer cell line PC3, either sensitive or made resistant to docetaxel. [Anticancer Drugs] Abstract


Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase III Study
Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase III study. Scientists presented the final analysis of the study before crossover from placebo to abiraterone acetate. [Lancet Oncol] Abstract

Targeting p53 In Vivo: A First-in-Human Study with p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Researchers aimed to determine maximum-tolerated dose, safety, dose-limiting toxicities, and pharmacokinetics of APR-246. APR-246 was administered as a two-hour intravenous infusion once per day for four consecutive days in 22 patients with hematologic malignancies and prostate cancer. [J Clin Oncol] Abstract | Press Release

Detect 7 times more prostate epithelial progenitors with ProstaCult


Androgen Receptor on the Move: Boarding the Microtubule Expressway to the Nucleus
The authors highlight the importance of signaling and trafficking pathways that depend on intact and dynamic microtubules, and, as such, they represent downstream targets of microtubule inhibitors. They showcase prostate cancer, which is driven by the activity of the androgen receptor, as recent reports have revealed a connection between the microtubule-dependent trafficking of the androgen receptor and the clinical efficacy of taxanes. [Cancer Res] Abstract | Press Release

Targeting the Androgen Receptor Signaling Axis in Castration-Resistant Prostate Cancer

This review provides an update in the development of several novel agents targeting the androgen receptor signaling pathway now in clinical testing, and reviews novel therapies in development with distinct mechanisms of action showing promising preclinical activity. [BJU Int] Abstract


NewLink Announces an Investigator Initiated Phase II Study of Sipuleucel-T Plus Indoximod in the Treatment of Certain Men with Advanced Prostate Cancer
NewLink Genetics announced that it will begin an investigator initiated, randomized, double blind placebo controlled phase II study entitled “Phase II Study of sipuleucel-T (PROVENGE®) plus indoximod (D-1MT/NLG8189) in the treatment of patients with asymptomatic or minimally symptomatic metastatic hormone refractory prostate cancer.” [NewLink Genetics Corporation ] Press Release

CureVac Secures €80 Million in Series D Financing
CureVac GmbH announced the completion of an €80 million financing round with its main investor, dievini Hopp BioTech Holding. CureVac will use the proceeds mainly to advance the development of its two lead RNActive® cancer vaccines against prostate cancer and non-small cell lung cancer, respectively. [CureVac GmbH] Press Release

Medivation and Astellas Announce XTANDI® (Enzalutamide) Is Now Available for Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel
Medivation, Inc. and Astellas Pharma Inc. announced the availability of XTANDI® capsules for patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. [Astellas Pharma Inc.] Press Release

$8.7 Million Awarded to Stem Cell Researchers in Clinical & Basic Biology Grants from the State Stem Cell Agency
Nelson’s Early Translational award and the two Basic Biology IV grants, totaling $8.7 million, continue efforts by the California Institute of Regenerative Medicine to support research designed to take stem cell science from the laboratory to the clinic. [Eli and Edythe Broad Stem Cell Research Center at UCLA] Press Release


European Union Battles Over Research Billions
Tens of billions of euros are at stake as negotiations ramp up to shape Europe’s next seven-year research program. The discussions will cover familiar divisions over applied versus basic research and conflicting national agendas, but the continent’s ongoing financial problems will add an extra measure of anxiety. [European Commission, European Union]
Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


NEW BIT’s 3rd Annual World Congress of Molecular & Cell Biology
June 14-16, 2013
Suzhou, China

our events page to see a complete list of events in the prostate cell community.


Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Product Manager – Hematopoietic (STEMCELL Technologies, Inc.)

Postdoctoral Position – Prostate Cancer (BC Cancer Agency)

Postdoctoral Position – Prostate Cancer Metastasis (Lund University)

Postdoctoral Position – Prostate Cancer (Sunnybrook Research Institute)

Research Associate – Quality Assurance (University of California)

Senior Postdoctoral Position – Endocrinology and Therapeutics of Prostate Cancer (Baylor College of Medicine)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us